Posted by Michael Wonder on 23 Oct 2025
Electra Therapeutics receives FDA breakthrough therapy and EMA priority medicines designations for ELA026 in secondary haemophagocytic lymphohistiocytosis
22 October 2025 - Electra Therapeutics today announced that ELA026 has received US FDA breakthrough therapy designation and EMA Priority Medicines (PRIME) designation for the treatment of secondary hemophagocytic lymphohistiocytosis.
ELA026, Electra’s lead drug candidate, is the first investigational therapy to receive BTD and PRIME designations for secondary hemophagocytic lymphohistiocytosis, underscoring its potential to address this life-threatening condition with significant unmet medical need.
